Why Erasca, Inc.’s (ERAS) Stock Is Up 7.72%
As of Thursday, September 10, Erasca, Inc.’s ERAS share price has surged by 7.72%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Commentary & Analysis
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.37%
As of Wednesday, September 02, Erasca, Inc.’s ERAS share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Michael Rose
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.49%
As of Friday, August 28, Erasca, Inc.’s ERAS share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Michael Rose
Why Erasca, Inc.’s (ERAS) Stock Is Up 8.67%
As of Wednesday, August 26, Erasca, Inc.’s ERAS share price has surged by 8.67%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Erasca, Inc.’s (ERAS) Stock Is Up 5.80%
As of Friday, August 21, Erasca, Inc.’s ERAS share price has surged by 5.80%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,683.6 | $262.9 | 69% |
|
| Shares Out (Mil) | 311.3 | 54.4 | 83% |
|
| Institutional Ownership | 86.8% | 92.9% | 55% |
|
| Float (Mil) | 242.9 | 41.5 | 77% |
|
| Beta | 0.65 | 0.94 | 38% |
|
| Avg Daily Volume (000s) | 4,414 | 496 | 92% |
|
| Price Change (52-week) |
941.7% | 54.5% | 100% |
|
| Growth | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (4.1%) | (10.1%) | 35% |
|
| EPS (5yr) | 38.1% | 15.8% | 88 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (59.0%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.130) | ($0.976) | ($0.623) | |
| Month Ago EPS | ($0.125) | ($0.966) | ($0.582) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.124) | ($0.966) | ($0.575) | |
| Year/Year Chg | (8.5%) | 122.3% | 78.4% | |
| Financials | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($287) | ($43) | 5% |
|
| EPS (TTM) | ($0.971) | ($1.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($98) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($24) | $2 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $39 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $6,159 | $179 | 66% |
|
| Valuation | ERAS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.01 | 2.56 | 94% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.2% | na |
|
| Net Margin | na | (73.0%) | na |
|
| ROA | (65.2%) | (47.9%) | 9% |
|
| ROE | (78.2%) | (55.0%) | 11% |
|
| Liabilities to Assets | 16.8% | 29.4% | 11% |
|
| F-Score | 1 | 2 | 1% |
|
Erasca, Inc. did not pass any screens on 9/15/2026.
